ST葫芦娃：两款药品获得药品注册证书

Core Viewpoint - ST HuLuWa has received approval from the National Medical Products Administration for two new drug registrations, indicating a significant advancement in its product pipeline and potential market opportunities in diabetes and respiratory disease treatments [1] Group 1: Drug Approvals - The company has obtained drug registration certificates for Metformin and Empagliflozin Tablets (I) and Inhaled Compound Ipratropium Bromide Solution [1] - Metformin and Empagliflozin Tablets (I) are indicated for adult patients with type 2 diabetes, aimed at improving blood sugar control when used alongside diet and exercise [1] - The inhaled compound solution is intended for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm associated with obstructive airway diseases [1] Group 2: Regulatory Compliance - Both drugs were approved based on the technical requirements for quality and efficacy consistency with reference preparations, which aligns with the standards for generic drug quality and efficacy evaluation [1]